Short answer
CVRx, Inc. (CVRX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $14M (down 5.8% year over year) with net income of −$14M.
Q3 2026 key financials · XBRL
- Revenue
- $14M
- −5.8% YoY · −11.9% QoQ
- Net income
- −$14M
- −10.0% YoY · −0.8% QoQ
- Operating margin
- -94.3%
- Gross margin
- 86.7%
- EPS (diluted)
- −$0.52
- −6.1% YoY · +1.9% QoQ
Source: XBRL data from the CVRx, Inc. (CVRX) Q3 2026 10-Q on SEC EDGAR. USD.
CVRx, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $13.8M, down 6% YoY from $14.7M
- Gross margin 87% vs 87% YoY; net loss $14.2M vs $12.9M
- U.S. revenue $13.0M, down 4%; Europe weakest, $0.9M, down 27%
- Cash $58.7M vs $75.7M at December 31, 2025; nine-month operating cash use $31.9M
- Near-term headwinds: lower sales productivity, payer approval declines, specialist turnover; expense reductions implemented
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- Regulatory risk: Continued compliance obligations for medical-device operations
- Operational risk: Dependence on successful commercialization of CVRx products
- Financial risk: Potential need for additional capital to fund operations and growth
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CVRx, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.